Metrics as of 10/13/2026, 06:51 PM (Berlin time), refresh in progress.
MAIA Biotechnology Stock
MAIA Biotechnology, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Vlad Vitoc
- Employees
- 13
- Market cap
- $70 M
- IPO
- 28/07/2022
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual…
MAIA Biotechnology stock: price history
1D
-1.7%
1W
-2.5%
1M
-10.8%
6M
-15.3%
YTD
-24.2%
1Y
-26.1%
2Y
-57.2%
5Y
–
10Y
–
Next earnings date
Next earnings date
06/11/2026 (in 20 days)
Volatility around earnings
~22% stronger price swings than usual
Ask the agents about MAIA Biotechnology
MAIA Biotechnology stock metrics
P/E
-1.82
P/B
3.4
EV/EBITDA
-2.49
RETURN ON EQUITY
-38.4%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
131.6%
FLOAT SHARES
79,985,829
AVG. DAILY VOLUME (30D)
602,055
Insider transactions (SEC)
Vitoc Vlad
Guerrero Ramiro
Guerrero Ramiro
Guerrero Ramiro
Guerrero Ramiro
Institutional holders
Comparable stocks
Frequently asked questions about MAIA Biotechnology stock
What does MAIA Biotechnology do?
MAIA Biotechnology, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Vlad Vitoc, the company employs around 13 people.
The IPO was on 28/07/2022; the stock trades on AMEX under the ticker MAIA.
When does MAIA Biotechnology report next?
The next earnings date is 06/11/2026.
Around past earnings, price swings were roughly 22% stronger than usual.
Does MAIA Biotechnology pay a dividend?
No, MAIA Biotechnology currently does not pay a dividend.
Which stocks are comparable to MAIA Biotechnology?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get MAIA Biotechnology stock analyzed?
Clicking "Analyze stock" lets five strategies assess MAIA Biotechnology against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.